BioSpace News Archive

Delivers patient satisfaction*¹ and improved engagement¹ by allowing patients to do physical therapy at home, on demand and without using wearable sensors

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced its quantitative COVID-19 IgG antibody test achieved CE Mark.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the company’s efforts to advance health and equity, minimize its impact on the planet and dedicate itself to quality, ethics and transparency.

OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology drug development company focused on treating diabetic retinopathy earlier to preserve vision and avoid intravitreal injections, today announced the appointment of Brent Saunders, Robert Ruffolo, Ph.D., and Robin Steele to its Board of Directors

Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform , today announced that Elizabeth Radcliffe has joined the company as Chief Financial Officer.

$38.1M in Rubraca ® (rucaparib) global net product revenues for Q1 2021, down 11% vs. Q1 2020, due to continued headwinds from COVID-19 in the US and Europe Maintained US market share as US PARP inhibitor market impacted by COVID-19 Imaging and treatment INDs cleared by FDA for FAP-2286, a novel peptide-targeted radionuclide therapy (PTRT) T

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s manufacturing partner Empowered Diagnostics has filed for emergency approval to use ImmunoPass™, the Company’s rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies,

OncoRes Medical has received a Breakthrough Device designation from the U.S. Food and Drug Administration to expedite development of its Quantitative Micro-Elastography (QME) Imaging System

Caron Products and Services (“Caron”), a leading provider of laboratory equipment used in small and large molecule drug development and manufacturing, cell and gene therapy, and academic research, is pleased to announce the appointment of Mark McLoughlin to its Board of Directors.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced the first surgeries using the new Archer™ R1 Reverse Shoulder System.